CN115518219B - Low-capacity activated leukocyte adsorber - Google Patents
Low-capacity activated leukocyte adsorber Download PDFInfo
- Publication number
- CN115518219B CN115518219B CN202211057321.6A CN202211057321A CN115518219B CN 115518219 B CN115518219 B CN 115518219B CN 202211057321 A CN202211057321 A CN 202211057321A CN 115518219 B CN115518219 B CN 115518219B
- Authority
- CN
- China
- Prior art keywords
- adsorption film
- adsorber
- blood
- end cover
- low capacity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 14
- 238000001179 sorption measurement Methods 0.000 claims abstract description 68
- 239000008280 blood Substances 0.000 claims abstract description 40
- 210000004369 blood Anatomy 0.000 claims abstract description 38
- 239000007787 solid Substances 0.000 claims abstract description 14
- 239000011162 core material Substances 0.000 claims description 8
- 238000003466 welding Methods 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 239000012528 membrane Substances 0.000 description 29
- 230000002757 inflammatory effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The utility model relates to the technical field of medical appliances and discloses a low-capacity activated leukocyte adsorber, which comprises end covers and a shell, wherein the two end covers are respectively connected with two ends of the shell to form a closed cavity, a blood inflow port is formed in one end cover, a blood outflow port is formed in the other end cover, an adsorption film is arranged in the closed cavity, the adsorption film is wrapped by an adsorption film supporting structure and is coiled into a spiral shape, the adsorption film supporting structure is a uniformly arranged blood guide tube, the blood guide tube comprises a solid section of a middle part and hollow pipelines at two ends, and side holes are formed in the joint of the hollow pipelines and the solid section. The utility model can ensure the sufficient contact between the blood and the adsorption film, avoid poor blood flowing performance, has better effect of removing activated leucocytes, and can reduce the pre-charge of the leucocyte adsorber.
Description
Technical Field
The utility model relates to the technical field of medical equipment, in particular to a low-capacity activated leukocyte adsorber.
Background
Systemic Inflammatory Response Syndrome (SIRS) refers to a clinical syndrome that occurs in the body due to uncontrolled inflammatory response, such as extracorporeal circulation, infection, trauma, burns, pancreatitis, heat-jet disease, etc. The mechanism is the excessive activation of inflammatory cells and the massive release of inflammatory mediators, and the sustained, uncontrollable inflammatory response will lead to organ dysfunction and even death. However, there is currently a lack of effective treatments.
For years, intervention strategies for SIRS have undergone methods of immunosuppression, cytokine monoclonal antibodies, inhibition of inflammatory response pathways, etc., but the results have been disappointing. The reason for this is the indiscriminate inhibition of the drug, which can lead to excessive immunosuppression and also to inflammatory injury. The reconstitution of the balance of host immune response, inflammatory response, may be critical to improve patient prognosis.
The existing adsorption removal inflammatory cytokines mode treats SIRS, can remove circulating inflammatory cytokines; inflammatory factors are released mainly by activated inflammatory cells, secondary to tissue injury. Circulating inflammatory cells activate, penetrate the membrane into the tissue, and release inflammatory factors exacerbating the local inflammatory response. The adsorber eliminates circulating inflammatory factors and does not eliminate inflammatory cells, thus affecting tissue inflammatory response very rarely.
The Chinese patent No. 103495218B (publication date: 2016-10-12) discloses an activated cell adsorber, a control system and a control method thereof, and the Chinese patent No. CN215821881U (publication date: 2022-02-15) discloses an activated leukocyte adsorber, wherein the adsorption mode is adopted to replace the filtration mode, and according to the characteristics of a membrane material, blood is changed into blood which passes through the surface of the membrane material, so that activated cells with adhesive characteristics are retained on the surface of the membrane material and removed, and unactivated cells without adhesive characteristics are still remained in the blood, thereby achieving the purpose of selectively removing the activated cells. The above patent has the following problems in practical application: (1) The blood film led into the surface of the film is thicker, which is not beneficial to the full contact between the blood and the film material; (2) The blood flow performance is poor, partial blood can be remained in dead corners of the absorber and cannot flow fully, so that the membrane material is wasted, and thrombus can be caused; (3) To achieve adequate membrane surface area, the adsorbers require a very large volume, thus resulting in a large pre-load, which can result in increased dilution of the blood and waste of blood.
Disclosure of Invention
In order to solve the defects in the prior art, the utility model provides a low-capacity activated leukocyte adsorber, which ensures that blood is fully contacted with the surface of a membrane material and reduces the pre-charge.
In order to achieve the technical purpose, the utility model adopts the following technical scheme:
the utility model provides a low-capacity activated leucocyte adsorber, includes end cover, shell, two the end cover is connected with the shell both ends respectively, forms closed cavity, has seted up blood inflow mouth on one end cover, has seted up blood outflow mouth on the other end cover, be equipped with the adsorption membrane in the closed cavity, the adsorption membrane parcel has the adsorption membrane bearing structure to roll up into heliciform, the adsorption membrane bearing structure is the blood guide tube of evenly arranging, the adsorption membrane bearing structure includes the solid section of mid portion and the hollow pipeline at both ends, and hollow pipeline and solid section junction are equipped with the side opening.
Further, the side holes are arranged in a plurality, and are uniformly distributed around the periphery of the hollow pipeline.
Preferably, two side holes are arranged.
Further, the end surfaces of the two ends of the solid section of the adsorption film supporting structure are arc-shaped and outwards convex.
Further, the two ends of the adsorption film supporting structure are fixed with the two ends of the adsorption film through bonding, and a gap is reserved between the adsorption film and the adsorption film supporting structure between the side holes at the two ends of the adsorption film supporting structure.
Further, the adsorption film is coiled into a spiral shape by taking the support core in the adsorption film as a core material.
Preferably, the end cover and the shell are fixed by ultrasonic welding.
Preferably, the end cover and the shell are bonded and fixed by medical glue.
Compared with the prior art, the utility model has the beneficial effects that:
the utility model adopts the activated cell adsorption technology to effectively remove the circulating activated leucocytes, the adsorption membrane supporting structure adopts a structure form that the middle is solid and the two ends are hollow tubular, so that the blood membrane contacted with the adsorption membrane is thinned, thereby ensuring the full contact between the blood and the adsorption membrane, avoiding poor blood flow performance, having better effect of removing the activated leucocytes and reducing the pre-charge of the leucocyte adsorber.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings that are needed in the embodiments will be briefly described below, it being understood that the following drawings only illustrate some embodiments of the present application and therefore should not be considered limiting the scope, and that other related drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a schematic diagram of the structure of the present utility model;
FIG. 2 is an enlarged view at line A of FIG. 1;
FIG. 3 is a cross-sectional view of the present utility model;
FIG. 4 is an enlarged view at line B of FIG. 3;
FIG. 5 is an expanded schematic view of the adsorption membrane and the adsorption membrane support structure according to the present utility model;
FIG. 6 is a schematic perspective view of an adsorption membrane support structure of the present utility model;
fig. 7 is a cross-sectional view of fig. 6.
Reference numerals: 1-blood outflow port, 2-end cover, 3-shell, 4-adsorption membrane, 5-adsorption membrane inner support core, 6-adsorption membrane support structure, 61-solid section, 62-hollow pipeline, 63-side hole, 7-blood inflow port.
Detailed Description
For the purposes of making the objects, technical solutions and advantages of the embodiments of the present application more clear, the technical solutions of the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is apparent that the described embodiments are some embodiments of the present application, but not all embodiments. The components of the embodiments of the present application, which are generally described and illustrated in the figures herein, may be arranged and designed in a wide variety of different configurations. Thus, the following detailed description of the embodiments of the present application, as provided in the accompanying drawings, is not intended to limit the scope of the application, as claimed, but is merely representative of selected embodiments of the application. All other embodiments, which can be made by one of ordinary skill in the art based on the embodiments herein without making any inventive effort, are intended to be within the scope of the present application.
1-5, including end caps 2, outer cover 3, two said end caps 2 are connected with both ends of outer cover 3 separately, form the closed cavity, offer the blood inflow port 7 on an end cap, offer the blood outflow port 1 on another end cap, there are adsorption membranes 4 in the said closed cavity, the said adsorption membrane 4 is activated leucocyte adsorption membrane, the adsorption membrane 4 wraps up and has the support structure 6 of the adsorption membrane, the support structure 6 of the said adsorption membrane is the blood guide tube that is distributed evenly, the support structure of the said adsorption membrane includes the solid section 61 of the middle part, and hollow conduit 62 of both ends, the hollow conduit 62 links with solid section 61 and has side openings 63; the adsorption film 4 takes the adsorption film internal support core 5 as a core material or is directly coiled into a spiral shape without the core material, the adsorption film support structure 6 supports two adjacent layers of adsorption films, gaps are formed between the layers, blood enters through the hollow pipeline 62 at the blood inflow port end and flows out from the side hole 63 at the end, the blood flows between the surface of the adsorption film support structure 6 and the adsorption film, activated white blood cells in circulating blood are fully adsorbed by the adsorption film 4 and flow to the blood outflow port end, and the blood flows out through the side hole at the blood outflow port end and enters into the hollow pipeline. The side holes 63 are provided in a plurality, for example, 2, 3, 4, and are uniformly distributed around the outer circumference of the hollow pipe.
The adsorption film supporting structure 6 effectively supports two adjacent adsorption films, reduces the thickness of blood films, and is beneficial to the full contact between blood and a film material; the middle part is a solid cylinder, the surface of the adsorption film is fully utilized, the volume of the adsorption film is reduced, the pre-charge is reduced, the support function is realized, and the collapse of the adsorption film is avoided; the blood inflow port end is the hollow pipeline that has the side opening, and the blood of being convenient for flows out from the side opening and gets into in the adsorption film and fully adsorbs, and the blood outflow port end is the hollow pipeline that has the side opening, and the blood of being convenient for flows in the hollow cylinder pipeline from the side opening and flows out again, increases the blood flow property, effectively avoids the formation at dead angle.
Further, the two ends of the solid section 61 of the adsorption film supporting structure 6 are arc-shaped and convex outwards, so that blood is prevented from accumulating.
Further, two ends of the adsorption film supporting structure 6 are fixed with two ends of the adsorption film 4 through bonding, and a gap is reserved between the adsorption film and the adsorption film supporting structure 6 between the side holes at two ends of the adsorption film supporting structure 6; the end cover and the shell are fixed through ultrasonic welding or medical adhesive.
Of course, the present utility model is capable of other various embodiments and its several details are capable of modification and variation in light of the present utility model by one skilled in the art without departing from the spirit and scope of the utility model as defined in the appended claims.
Claims (8)
1. The utility model provides a low capacity activation leucocyte adsorber, includes end cover (2), shell (3), two end cover (2) are connected with shell (3) both ends respectively, form closed cavity, have seted up blood inflow port (7) on one end cover, have seted up blood outflow port (1) on the other end cover, be equipped with adsorption film (4) in the closed cavity, adsorption film (4) parcel has adsorption film bearing structure (6) to roll up heliciform, its characterized in that: the adsorption film support structure (6) is a uniformly arranged blood guide tube, and comprises a solid section (61) at the middle part and hollow pipelines (62) at the two ends, wherein a side hole (63) is formed at the joint of the hollow pipelines (62) and the solid section (61); and a gap is reserved between the adsorption film (4) and the adsorption film supporting structure (6) between the side holes (63) at the two ends of the adsorption film supporting structure (6).
2. The low capacity activated leukocyte adsorber of claim 1 wherein: the side holes (63) are arranged in a plurality, and are uniformly distributed around the periphery of the hollow pipeline.
3. The low capacity activated leukocyte adsorber of claim 2 wherein: two side holes (63) are arranged.
4. The low capacity activated leukocyte adsorber of claim 1 wherein: the two ends of the solid section (61) of the adsorption film supporting structure (6) are arc-shaped and outwards convex.
5. The low capacity activated leukocyte adsorber of claim 1 wherein: two ends of the adsorption film supporting structure (6) are fixed with two ends of the adsorption film (4) through bonding.
6. The low capacity activated leukocyte adsorber of claim 1 wherein: the adsorption film (4) is coiled into a spiral shape by taking the support core (5) in the adsorption film as a core material.
7. The low capacity activated leukocyte adsorber of claim 1 wherein: the end cover (2) and the shell (3) are fixed by ultrasonic welding.
8. The low capacity activated leukocyte adsorber of claim 1 wherein: the end cover (2) and the shell (3) are adhered and fixed by medical glue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211057321.6A CN115518219B (en) | 2022-08-30 | 2022-08-30 | Low-capacity activated leukocyte adsorber |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211057321.6A CN115518219B (en) | 2022-08-30 | 2022-08-30 | Low-capacity activated leukocyte adsorber |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115518219A CN115518219A (en) | 2022-12-27 |
| CN115518219B true CN115518219B (en) | 2023-06-16 |
Family
ID=84698162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211057321.6A Active CN115518219B (en) | 2022-08-30 | 2022-08-30 | Low-capacity activated leukocyte adsorber |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115518219B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108404239A (en) * | 2018-02-11 | 2018-08-17 | 武汉瑞法医疗器械有限公司 | Integral type blood plasma detaches myoglobins absorber |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3839204A (en) * | 1972-04-27 | 1974-10-01 | Gen Electric | Integral blood heat and component exchange device and two flow path membrane blood gas exchanger |
| US4636310A (en) * | 1982-12-07 | 1987-01-13 | Bellhouse Brian John | Transfer membrane apparatus |
| ATE485067T1 (en) * | 2005-08-31 | 2010-11-15 | Gambro Lundia Ab | METHOD AND DEVICE FOR REMOVAL OF IMMUNE CELLS |
| US8679063B2 (en) * | 2009-02-11 | 2014-03-25 | Becton, Dickinson And Company | Systems and methods for providing a catheter assembly |
| CN103041708B (en) * | 2012-12-28 | 2015-01-07 | 成都连接流体分离科技有限公司 | High-pollution-resistance roll type membrane component |
| CN103495218B (en) * | 2013-10-21 | 2016-10-12 | 四川大学华西医院 | Activating cell adsorber and control system thereof and control method |
| CN204619759U (en) * | 2015-03-27 | 2015-09-09 | 浙江美易膜科技有限公司 | For the rolling microtubular membrane assembly of external membrane bioreactor |
| EP3679964A4 (en) * | 2017-09-08 | 2021-06-02 | Toray Industries, Inc. | Immunosuppressive leukocyte adsorption material and adsorption column |
| CN216653011U (en) * | 2021-01-19 | 2022-06-03 | 西安西京医疗用品有限公司 | Membrane oxygenator for blood purification |
| CN114796664A (en) * | 2021-01-19 | 2022-07-29 | 西安西京医疗用品有限公司 | Blood purification device and purification method thereof |
| CN215821881U (en) * | 2021-07-15 | 2022-02-15 | 四川大学华西医院 | Activated leukocyte adsorber |
| CN114632423A (en) * | 2022-04-06 | 2022-06-17 | 创脉医疗科技(上海)有限公司 | Membrane module system, gas exchange and desorption system and blood oxygenator |
-
2022
- 2022-08-30 CN CN202211057321.6A patent/CN115518219B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108404239A (en) * | 2018-02-11 | 2018-08-17 | 武汉瑞法医疗器械有限公司 | Integral type blood plasma detaches myoglobins absorber |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115518219A (en) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8303555B2 (en) | Soft collector for a negative pressure wound therapy system and its combination | |
| EP1922097B1 (en) | Method and apparatus for the removal of immune cells | |
| CN115518219B (en) | Low-capacity activated leukocyte adsorber | |
| WO2023284151A1 (en) | Integrated membrane oxygenator | |
| CN106139289A (en) | Semipermeable membrane layering integrated biological reactor | |
| CN215821881U (en) | Activated leukocyte adsorber | |
| JPS62243561A (en) | Leucocyte removing filter device | |
| CN209075640U (en) | A kind of haemodialysis extracorporeal circulation pipeline | |
| CN210844572U (en) | Blood perfusion device and blood purification equipment | |
| CN219462091U (en) | Hemodialysis adsorber | |
| CN201171832Y (en) | Disposable blood virus inactivation filter | |
| CN207203790U (en) | A kind of activated carbon filter cylinder | |
| CN206652028U (en) | Outside multi-pipeline converter for negative-pressure sealed drainage system | |
| CN115607760A (en) | Activated leukocyte adsorber | |
| CN201040115Y (en) | Thin membrane type white blood cell filter | |
| CN201510566U (en) | Arterial microemboli filter | |
| CN204890747U (en) | Hemodialysis machine | |
| CN213789210U (en) | Semi-isolation type artery and vein kettle device | |
| CN220695618U (en) | Anti-adhesion high-efficiency suction drainage dressing | |
| JPS631538U (en) | ||
| CN212214764U (en) | Medical filter | |
| CN220025773U (en) | Disposable medicine liquid filter for transfusion | |
| JPS6317484Y2 (en) | ||
| CN210542633U (en) | Hemodialysis pipeline capable of emptying without separating puncture needle | |
| CN217604398U (en) | Plate core structure of flat-plate solar collector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240112 Address after: No. 1506, 15th Floor, Building 1, No. 1800 Yizhou Avenue Middle Section, Chengdu High tech Zone, China (Sichuan) Pilot Free Trade Zone, Chengdu City, Sichuan Province, 610000 Patentee after: Chengdu Shangyuantai Biotechnology Co.,Ltd. Address before: No. 37, Wuhou District National School Lane, Chengdu, Sichuan Province Patentee before: WEST CHINA HOSPITAL, SICHUAN University |
|
| TR01 | Transfer of patent right |